Results 91 to 100 of about 6,088 (209)

Refractory diffuse large B-cell Lymphoma

Journal of Taibah University Medical Sciences, 2023
Hajar Masrour, Latifa Lerhrib, Sanaa Bouchnafati, Widad Rhandour, Mounia Bouzayd, Laila Abarkan, Anas Oudrhiri, Nabil Al Saddiq, Rim Hanini, Yassine Chekkori, Falah Eddine Tohir, Ouazzani, Naoual Oubelkacem, Noufissa Alami Drideb, Zineb Khammar, Rhizlane Berrady   +15 more
doaj   +1 more source

Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies

Journal of Hematology & Oncology
Diffuse large B-cell lymphoma (DLBCL) is an aggressive, yet curable malignancy, that has had practice changing treatment approvals in both the frontline and relapsed setting in the last 5 years. Advent of novel therapeutic options in the recent years has
Allison M. Bock, Narendranath Epperla
doaj   +1 more source

Nanoagonist‐mediated spatiotemporal reprogramming of macrophage phenotypes to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes the major molecular mechanisms governing TAM polarization and their coordinated interactions. It further highlights recent advances in nanoagonist‐based strategies that intervene in these pathways to reprogram TAMs, critically discussing their therapeutic potential, current limitations, and translational prospects.
Siqi Fang, Fengfeng Xiao, Ruie Chen, Cuixia Lu, Yi Ju, Mingqing Yuan, Yunlu Dai, Liewei Wen   +7 more
wiley   +1 more source

Risk of Bias Associated with Varying Sampling Strategies for External Comparator Cohorts for Single‐Arm Trials: Insights from Aggressive Lymphoma

Clinical Pharmacology &Therapeutics, EarlyView.
Marketing authorizations for oncology drugs are often based on single‐arm trials (SATs), and real‐world data‐based external comparator cohorts (ECCs) are increasingly explored to contextualize results. In retrospective studies, comparators may be identified by time of diagnosis but included based on time of relapse; such sampling strategies can ...
Mikkel Runason Simonsen, Shiva Leisner, Ahmed Ludvigsen Al‐Mashhadi, Laurids Østergaard Poulsen, Matthew Maurer, Lasse Hjort Jakobsen, Tarec Christoffer El‐Galaly   +6 more
wiley   +1 more source

Challenges and Pitfalls to Diagnosing NUTM1‐Rearranged Neoplasia of the Pancreas by Cytology and Ancillary Studies

Diagnostic Cytopathology, EarlyView.
ABSTRACT Fine‐needle aspiration cytology specimens are frequently utilized for ancillary studies to identify diagnostic and prognostic information. This case highlights diagnostic pitfalls and challenges in diagnosing NUTM1‐rearranged neoplasia on pancreatic cytology.
Terrance J. Lynn
wiley   +1 more source

Pathophysiology and molecular aspects of diffuse large B-cell lymphoma

Revista Brasileira de Hematologia e Hemoterapia, 2012
Diffuse large B-Cell lymphoma is the most common subtype of non-Hodgkin lymphoma in the West. In Brazil, it is the fifth cause of cancer, with more than 55,000 cases and 26,000 deaths per year.
Gisele Rodrigues Gouveia, Sheila Aparecida Coelho Siqueira, Juliana Pereira   +2 more
doaj  

Diagnostic Usefulness of Cell Block Samples in Fluid Overload‐Associated Large B‐Cell Lymphoma

Diagnostic Cytopathology, EarlyView.
ABSTRACT Fluid overload‐associated B‐cell lymphoma (FO‐LBCL) is a B‐cell neoplasm that presents as serous effusions without detectable tumor masses and Kaposi sarcoma‐associated herpesvirus (KSHV)/human herpesvirus 8 (HHV8) infection. Here, we report a case of an 81‐year‐old female patient with FO‐LBCL (Stage IVA) who presented with pericardial and ...
Hiroyuki Okanishi, Hiroko Kuwabara, Hiroko Nakayama, Mayo Odaka, Kozue Ariga, Isako Kataoka, Mari Tomiuka, Mayumi Uragami, Chihiro Deguchi, Shizuka Ono, Reika Takeda, Yoshitaka Kurisu, Yoshinobu Hirose, Yuuki Kinoshita, Taiji Yokote   +14 more
wiley   +1 more source

Next‐Generation CAR‐T Cell Therapy: From Modular Design to Clinical Expansion

Exploration, EarlyView.
Over the past decades, chimeric antigen receptor (CAR)‐T cell therapy has evolved from a linear engineering concept into a powerful yet constrained immunotherapy, limited by tumour microenvironment barriers, immune evasion, and manufacturing complexity.
Yuesong Bai, Jintao Qin, Zongjun Dai, Ran Yan, Yong Yang, Wenguang Wang   +5 more
wiley   +1 more source

Cold versus warm autoimmune hemolytic anemia in diffuse large B cell lymphoma: pathogenic and therapeutic implications: a case series

Journal of Medical Case Reports
Background Autoimmune hemolytic anemia-associated diffuse large B cell lymphoma is rare, with distinct pathogenic mechanisms and therapeutic responses in cold agglutinin syndrome (CAS) and warm autoimmune hemolytic anemia subtypes poorly characterized ...
Zhiye Zhang, Xingxing Yu, Jingjing Li, Tianwen Gao   +3 more
doaj   +1 more source

High‐Grade B‐Cell Lymphoma With 11q Aberration in Africa: A Differential Diagnosis in Cases With Features of Endemic Burkitt Lymphoma

International Journal of Cancer, EarlyView.
ABSTRACT Fifty years ago, Zech et al. in this journal described for the first time the t(8;14) as a recurrent chromosomal aberration in Burkitt lymphoma (BL). Nevertheless, in regions where BL is not endemic, a subset of lymphomas with features of BL lacks the t(8;14)/IG::MYC and instead represents high‐grade B‐cell lymphoma with 11q aberration (HGBCL ...
Timothy Onyuma, Anja Fischer, Raffaella Guazzo, Mateus H. Gouveia, Noel Onyango, Cristiana Bellan, Susanne Bens, Roberto Boccacci, Michaela Feuring, Massimo Granai, Grace Kiraka, Alexandra G. Kouroukli, Stefano Lazzi, Cosimo Lori, Marianne Wanjiru Mureithi, Joshua Nyagol, Matthias Schlesner, Maria Chiara Siciliano, Margherita Vannucchi, Rabea Wagener, Nicholas Othieno‐Abinya, Sam M. Mbulaiteye, Lorenzo Leoncini, Reiner Siebert   +23 more
wiley   +1 more source